Connect to share and comment

Promise seen with Pfizer breast cancer drug

An experimental cancer drug made by Pfizer has shown signs of promise at slowing the spread of advanced breast cancer, researchers said. The drug, called palbociclib, when administered with another anti-cancer drug already on the market, letrozole, stopped cancer progression for a median of 20 months. That was double the amount of time seen in a control group of patients who did not receive palbociclib.

FDA allows Curis to resume testing cancer drug

(Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. The drugmaker's shares rose as much as 13 percent in morning trading on the Nasdaq. Enrolment for the study was halted after the death of a patient with advanced breast cancer, who experienced acute liver failure about a month after the drug, codenamed CUDC-427, was discontinued.

Radiation improves odds for some women after mastectomy

By Andrew M. Seaman NEW YORK (Reuters Health) - Women who have their breasts removed because of cancer may benefit from receiving radiation if they still have traces of cancer in their lymph nodes, suggests a new analysis. Radiation reduced the risk of death and of cancer returning among women who had cancer cells detected in the cluster of nodes under the arms after a mastectomy. The nodes are part of the lymphatic system, a conduit for immune and other cells.

Court denies Myriad motion to block rival genetic tests

(Reuters) - Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company. Myriad's shares fell 12 percent before the bell on Tuesday. Myriad's problems started last June when the U.S. Supreme Court ruled that the company could not patent naturally occurring human genes, curbing the company's monopoly over a type of gene-based cancer testing.

Aveo, Astellas end pact to develop cancer drug tivozanib

(Reuters) - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications. Aveo, which cut 62 percent of its workforce last year to focus on developing the drug, tivozanib, as a treatment for breast and colon cancers, said in December that the drug was not likely to succeed in a mid-stage trial testing its use in colon cancer. The companies said on Friday they would discontinue the study.

Nine breast cancer patients in Newfoundland had inaccurate breast cancer tests

ST. JOHN'S, N.L. - Nine patients in Newfoundland and Labrador had incorrect breast cancer test results, resulting in overly aggressive treatments for them, the province's largest health authority said Thursday. Eastern Health said it discovered a problem on Dec. 9, when it found a test result from its lab did not match with one during a quality assurance test. The health board said it stopped its testing at the lab and sent new tests to an external lab for follow-up.

Genome tests help tailored treatment for breast cancer

French doctors said on Friday they had used gene testing to help women with advanced breast cancer get access to clinical trials that may offer a better chance of treating their disease. The study, the biggest of its kind, improves the chances of getting drugs that, like a sniper's rifle, aim at a specific type of tumour, they said. Researchers led by Fabrice Andre, a professor at the Gustave Roussy Institute in Paris, unravelled the DNA of cancer cells found in more than 407 women whose breast cancer had spread dangerously to other tissues.

Pfizer's promising experimental breast cancer drug, palbociclib, meets study's survival goal

NEW YORK, N.Y. - Drugmaker Pfizer Inc. says a midstage study of its experimental drug for advanced breast cancer, palbociclib (pal-boh-SEYE'-clib), met the main goals. The world's second-biggest drugmaker says its drug, combined with another medicine called letrozole (LET'-rah-zole), increased the time patients survived without tumors growing, compared with women just getting letrozole. Pfizer shares jumped 99 cents, or 3.3 per cent, to $31.40 in late-morning trading.

Aveo Oncology to end breast cancer study due to low enrollment

(Reuters) - Aveo Oncology said it would end a mid-stage trial testing its lead drug as a treatment for breast cancer, as the company did not have enough patients enrolled in the study. Aveo, which was developing the drug with Japan's Astellas Pharma Inc, said enrollment in the study had been slower than expected and did not improve despite efforts to recruit more patients.

Biocon to start selling breast cancer drug in India in February

MUMBAI (Reuters) - Biocon Ltd said its generic version of Roche's Herceptin breast cancer treatment would be available to patients in India from the first week of February. Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc. About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.
Syndicate content